Biology of flushing could renew niacin as cholesterol drug

Apr 06, 2009

Deft molecular detective work at Duke University Medical Center suggests that scientists may soon be able to resurrect niacin as one of the best and cheapest ways to manage cholesterol.

Niacin, also known as nicotinic acid or vitamin B3, has long been regarded as one of the most effective weapons in managing cholesterol. It can lower levels of triglycerides, fatty acids and to a lesser extent, the "bad" kind of cholesterol (LDL) while at the same time powerfully increasing the "good" kind (HDL). But there's a catch - a big one. Patients don't like to take niacin because in most of them, it causes embarrassing, uncontrollable intense flushing, a rush of blood to the face and other skin surfaces accompanied by a prickling sensation.

Now, however, scientists have identified the discrete molecular pathways that are triggered when niacin enters the body, and they say that knowledge may lead to a revival of niacin-based treatments as therapies of choice. Their discovery appears online in the and is scheduled to appear in the journal's May 1 issue.

"This opens up whole new realms for drug discovery," says Robert Walters, M.D., a dermatologist at Duke and the lead author of the study. "Not only could it lead to new niacin-based therapies for cholesterol that patients could actually stick with, but it could also mean new treatments for flushing that comes with some types of allergic reactions, hives and other disorders."

The discovery builds upon a growing body of knowledge at Duke about G coupled , molecules that dot cell surfaces throughout the body and manage its response to drugs, hormones, pain, growth factors and many other incoming chemical signals. Robert Lefkowitz, M.D., a Howard Hughes Medical Institute investigator at Duke and the senior author of the study, was the first to identify these receptors and some of the roles they play in health and well-being.

Working together, Lefkowitz and Walters conducted various laboratory and animal experiments to track exactly what happens when niacin enters the body. Earlier, others had found that it first activates a specific G protein coupled receptor known as GP109A. This receptor, in turn, alerts other sets of proteins, including G proteins and a group referred to as beta-arrestins. One particular protein in that group, beta-arrestin1, was found to trigger the chemical reaction that led to flushing.

"Niacin stimulates production of a vasodilator that dramatically increases blood flow to the face, causing the flush and the hot, prickly sensation - and beta-arrestin1 is the culprit that enables that to happen," says Walters. "Interestingly, however, beta-arrestin1 plays no role whatsoever in niacin's ability to lower cholesterol and fatty acids. The G proteins do that."

The finding reinforces some of Lefkowitz's recent research that demonstrated that beta-arrestins, which often work in tandem with G proteins, can sometimes work independently of them, initiating their own signals.

Lefkowitz says the discovery opens the door to the possibility of developing a "biased ligand," a drug that would trigger GP109A, but not the beta-arrestins. "That might give us a way to keep all the lipid-modifying benefits of niacin, but isolate its downside," he said.

That might not be as simple as it sounds, however. Other studies suggest that enhancing niacin's ability to boost HDL may be more complex than what appears at, well, first blush.

"GPR109A receptors are most often found in fat, the spleen , adrenal glands and lungs - they are absent from the liver and intestines, where most HDL is made and metabolized, so there may well be other mechanisms of action for the beneficial effects of niacin in addition to those performed by GPR109A," says Lefkowitz.

Lefkowitz is a scientific founder of Trevena, a company that is developing G protein coupled receptor-targeted drugs.

Source: Duke University Medical Center

Explore further: Nervous system may play bigger role in infections than previously known

add to favorites email to friend print save as pdf

Related Stories

Niacin's role in maintaining good cholesterol

Jun 05, 2008

A research team has uncovered the likely target of niacin (vitamin B3) in the liver, which should provide a clearer picture of how this vitamin helps maintain adequate HDL-cholesterol levels in the blood and thus lower the ...

Researchers Discover How Lithium Works

Jan 14, 2008

Despite more than 30 years of widespread use of lithium to control psychiatric disorders, such as bipolar disorder, scientists have been uncertain about how this drug actually works on a molecular level.

Two beta blockers found to also protect heart tissue

Sep 15, 2008

(PhysOrg.com) -- A newly discovered chemical pathway that helps protect heart tissue can be stimulated by two of 20 common beta-blockers, drugs that are prescribed to millions of patients who have experienced heart failure.

Recommended for you

Stroke damage mechanism identified

7 hours ago

Researchers have discovered a mechanism linked to the brain damage often suffered by stroke victims—and are now searching for drugs to block it.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

cindyg
not rated yet Apr 07, 2009
The more I read about the salutary effects of niacin, the more surprised I am that niacin has remained relatively obscure. At the website cholesterolscore.com , a site that's primarily about niacin therapy, there are many studies & articles that support "Biology of flushing could renew niacin as cholesterol drug."

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.